Smith + Nephew will pay $180 million at closing and up to an additional $150 million based on financial performance, according to a Nov. 22 news release from the company.
CartiHeal is the developer of Agili-C, a biocompatible and resorbable scaffold that promotes knee cartilage regeneration. The technology is a treatment option for bone and cartilage lesions and is designed to treat a wide patient population.
The FDA granted Aligi-C breakthrough device designation status in October 2020 and premarket approval in March 2022.
The transaction is expected to close during the first quarter of 2024, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
